Rheumatoid Arthritis News

Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.

The FDA has approved Tofidence as the first tocilizumab biosimilar in the United States for the treatment of rheumatoid arthritis and other conditions, according to a statement from the manufacturer.

Patients with rheumatoid arthritis or osteoarthritis in rural areas are less likely to report in-person health care use, including physician visits and diagnostic tests, vs. those in urban areas, according to data.

Patients with inflammatory rheumatic diseases are as likely as the general population to contract COVID-19, but are at a higher risk for severe outcomes, including hospitalization and death, according to data.

New patients with rheumatoid arthritis are more likely to consider impact on physical function and the potential for adverse events when choosing therapy options, according to data published in BMC Rheumatology.

Medicare will begin offering coverage for PrismRA, a molecular diagnostic test that predicts treatment response in certain patients with rheumatoid arthritis, according to a press release from its manufacturer.

SAN DIEGO — Patient age and disease-related factors may be driving safety signals in medications used to treat rheumatoid arthritis and psoriatic disease, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

SAN DIEGO — The official EULAR definition of difficult-to-treat rheumatoid arthritis does not fully account for the problems the disease can present, according to a presenter at the Congress of Clinical Rheumatology West.

SAN DIEGO — Rheumatology research still offers too few head-to-head clinical trials of biologic medications to help clinicians manage rheumatoid arthritis, according to data presented at the 2023 Congress of Clinical Rheumatology West.

Patients with rheumatoid arthritis who receive TNF inhibitors are more likely to develop psoriasis vs. those treated with methotrexate, according to an analysis of more than 880,000 post-marketing reports published in Scientific Reports.